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Abstract
Bovine viral diarrhea virus (BVDV) is a major cause of economic loss in the cattle industry, worldwide. 
Infection results in reduced productive performance, growth retardation, reduced milk production, and 
increased susceptibility to other diseases leading to early culling of animals. There are two primary methods 
used to control the spread of BVDV: the elimination of persistently infected (PI) animals and vaccination. 
Currently, modified live or inactivated vaccines are used in BVDV vaccination programs, but there are safety 
risks or insufficient protection, respectively, with these vaccines. Here we report the development and 
efficacy of the first targeted subunit vaccine against BVDV. The core of the vaccine is the fusion of the BVDV 
structural protein, E2, to a single-chain antibody, APCH, together termed, APCH-E2. The APCH antibody 
targets the E2 antigen to the major histocompatibility type II molecule (MHC-II) present on antigen-
presenting cells. Industrial production of the vaccine is carried out using the baculovirus expression vector 
system (BEVS) using single-use manufacturing technologies. This new subunit vaccine induces strong BVDV-
specific neutralizing antibodies in guinea pigs and cattle. Importantly, in cattle with low levels of natural 
BVDV-specific neutralizing antibodies, the vaccine induced strong neutralizing antibody levels to above the 
protective threshold, as determined by a competition ELISA. The APCH-E2 vaccine induced a rapid and 
sustained neutralizing antibody response compared to a conventional vaccine in cattle. 
Introduction
Bovine viral diarrhea virus (BVDV) belongs to the genus Pestivirus, family Flaviviridae. This virus has a 
worldwide distribution and infects ruminants. BVDV infections cause a broad spectrum of clinical signs 
ranging from mild respiratory disease to fetal death, depending on the virulence of the virus and the 
reproductive and immune status of the host (Ridpath 2010). It is also one of the etiologic agents of Bovine 
Respiratory Disease (BRD), which is a major health problem and the main cause of economic losses in raising 
cattle (Griffin 1997). Infection of pregnant cows with BVDV in the first trimester of gestation can result in the 
production of a persistently infected (PI) animal (Grooms 2004). Cattle with a persistent infection are a long-
term threat to herd-mates because they shed BVDV for life and represent the main reservoir of the virus 
within the herd. More than 90% of new PI calves are born to healthy cows that became infected during 
gestation, the other 7% to 10% of PI calves are offspring of PI cows (Wittum et al. 2001). Vaccination against 
BVDV is an important component of prevention and control programs since it can prevent clinical signs, 
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inactivated vaccines are used in vaccination programs. Both have historical disadvantages; MLV in terms of 
safety and inactivated vaccines in terms of immunoprotection. Subunit vaccines provide the opportunity of 
developing safe and effective vaccines as has been shown with the new human recombinant vaccines against 
shingles (Herpes zoster) and meningitis B (Neisseria meningitidis group B) that have received US-FDA approval 
in recent years. In the field of veterinary medicine, the challenge is to produce a recombinant vaccine that 
induces a protective immune response at a cost affordable price.
The BVDV genome consists of a single-stranded, positive sense RNA molecule of approximately 12.3 kb in 
length. E2 is the major structural glycoprotein of the BVDV envelope and the most immunoprotective protein 
of the virus (Deregt et al. 1998; Fulton et al. 1997; Paton, Lowings, and Barrett 1992). Neutralizing antibodies 
(NAbs) induced in infected animals are mainly directed against E2 (Donis 1995) . The first attempt by our 
group to produce a protective subunit vaccine against BVDV was based on a secreted version of the BVDV E2 
glycoprotein. Sera from animals vaccinated with E2 neutralized several BVDV strains within a genogroup  
(Pecora et al. 2014; S. Bolin et al. 1988). Moreover, it was demonstrated that NAbs raised against E2 
prevented infection from BVDV (Bolin 1995; Toth et al. 1999; Pecora et al. 2015). The E2 subunit was initially 
expressed in stably transfected CHO-K1 cells, reaching a yield of 0.3 mg/L. The immunogenicity of this first 
generation E2 antigen vaccine was studied using guinea pigs, as a laboratory animal model, and field trials 
were conducted in cattle. Animals vaccinated with this E2 subunit vaccine developed high NAb titers and 
were  protected against viral infection (Pecora et al. 2016). Results obtained in this initial trial were promising, 
but the low quantity of antigen produced in the CHO-K1 cell-line made large scale commercial production 
cost inhibitory for veterinary medicine purposes. To address this issue, two important modifications were 
introduced: 1) the protein production system was changed to transgenic alfalfa plants (Medicago sativa, L.) 
and the viral E2 glycoprotein was targeted to the antigen-presenting cells (APC) in order to increases its 
immunogenicity.
The coding sequence of the BVDV E2 glycoprotein was fused to the coding sequence of APCH, a single 
chain antibody, creating a fusion gene termed APCH-E2. APCH is a single-chain antibody directed to the major 
histocompatibility complex type II  (MHC -II) antigen epitope and has been designated as a potent 
immunomodulating molecule in at least two different vaccine models, improving both humoral and cellular 
immune responses in immunized animals as it targets the antigen to the APCs (Gil et al. 2011; Pecora, 
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genome and the antigen was produced in alfalfa leaves, yielding up to 1 g/g (antigen/ wet alfalfa) and 
production of the fusion antigen remained stable after vegetative propagation. A methodology based on an 
aqueous two-phase system was standardized for concentration and partial purification of APCH-E2 from 
alfalfa. Guinea pigs intramuscularly immunized with leaf extracts developed high BVDV-specific NAb titers. In 
bovine vaccinated with 3 g of alfalfa produced APCH-E2, BVDV-specific NAbs were induced and vaccinated 
animals did not shed BVDV after a viral challenge (isolate 98/124, type IB) (Aguirreburualde et al. 2013). 
Results with transgenic alfalfa plants were promising, but there were two major issues that should be 
resolved in order to transform the plant-derived APCH-E2 antigen in an industrial product: 1) inhibitory 
scaling-up issues with the extraction and purification process, and 2) the unknown regulatory aspects for 
parenteral administration of a viral antigen derived from transgenic-plants.
With the aim of overcoming these difficulties, the APCH-E2 antigen construct was engineered into the 
baculovirus expression vector system (BEVS)(Pecora, Malacari, Pérez Aguirreburualde, et al. 2015). BEVS was 
chosen because of the system’s advantages: it is safe, easy to use, and readily amenable to manufacturing 
scale-up (Kost, Condreay, and Jarvis 2005). In 2017, after more than ten years of research and development, 
this baculovirus produced APCH-E2 antigen was the basis of the first subunit and targeted vaccine licensed to 
be used in cattle for the control of BVDV. To get the governmental approval a controlled field study with 
seronegative calves and a placebo control group was performed; the targeted vaccine was able to induce a 
strong immune response after inoculation with two doses, 30 days apart. At the peak of the immune 
response, 60-120 days post vaccination (dpv), the mean NAb titer was > Log10 4.2 and the mean NAb titer was 
> Log10 2 at 360 dpv. No animals on the placebo group presented antibody against BVDV over the course of 
the trial (Pecora, Malacari, Pérez Aguirreburualde, et al. 2015). Here, we report the immunogenicity and 
efficacy of this new APCH-E2 commercial vaccine as tested in guinea pigs and a field trial in cattle under 
normal production conditions. This BEVS derived APCH-E2 vaccine induced a strong antibody response in all 
vaccinated animals and correlated with protection in experimentally challenged calves (Aguirreburualde et al. 
2013; Pecora, Malacari, Perez Aguirreburualde, et al. 2015; Pecora et al. 2016).
Materials and Methods 
Antigen production: Recombinant baculovirus expressing the APCH-E2 (BEVS-APCHE2) antigen was 
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frugiperda (Sf9) cells were used to produce the recombinant fusion antigen. Sf9 cells were cultivated in a 
customized SF900 II Serum Free Medium (ThermoFisher) and cultured as shown in Figure 1. Briefly, Sf9 cells 
were multiplied using a series of static and shaking cultures with increasing volumes to cultivate enough cells 
to seed 10L of media in a single-use bioreactor (GE, WAVE™ 25).  Sf9 Cells were cultured at 27 ºC to a cell 
density of 1.5x106 cells/ml in the bioreactor culture, which was  then infected with the BEVS-APCHE2 virus at 
a multiplicity of infection (MOI) of 3 and incubated at 27 ºC for 120 h to produce the antigen. To purify the 
antigen, the culture is processed through a serious of filtration steps. The concentration of the APCH-E2 
antigen is determined via an in-house ELISA (Pecora et al. 2009). Harvested antigen is stored at 4 (±2) ºC prior 
to formulation.
Vaccine: Vedevax BLOCK® (Bioinnovo SA, Buenos, Aires, Argentina) is a pre-mixed, ready-to-use, 
BVDV vaccine formulated with a water-in-oil adjuvant. The vaccine is a two-dose regimen (3 ml/dose, $0.9 
USD/dose) administered 21-30 days apart to cattle 6 months or older. The vaccine is licensed in Argentina 
(File Nº: 0057519/2014) and Peru (File Nº: B.14.5.02.I.0016) and is the only one-of-its-kind in the world.
Conventional vaccine: is a commercially available reproductive Al(OH)3-adjuvant vaccine which 
contains inactivated BVDV in its formulation. The vaccine is a two-dose regimen (5 ml/dose, $0.5 USD/dose) 
administered 21-30 days apart to cattle 6 months or older.
Vaccination of guinea pigs: 5 guinea pigs per group were vaccinated twice, at day 0 and 21, with 0.6 
ml (1/5 of the bovine dose) and bled 30 days post-second vaccination. Sera were analyzed by Virus 
Neutralization (VN) assay. According to a dose response assay conducted in guinea pigs and bovines using 
vaccines formulated with increasing titers of BVDV per dose (1x106, 1x107,or 1x108 TCID50/dose), a vaccine 
can be classified as of Not Satisfactory immunogenicity if the induced mean NAb titer in guinea pig was lower 
than 1:24 (Log10 titer< 1.37), of Satisfactory immunogenicity if 1:24 ≤ NAbs titer ≤ 1:100 (Log10 1.37 ≤ NAbs 
titer ≤ Log10 2),  or of Highly Satisfactory immunogenicity if  the mean NAbs titer ≥ 1:100 (Log10 titer > 2). (Res. 
SENASA 2012).
Virus Neutralization (VN) assay: The cytopathic BVDV-1a (Singer strain) was used in the VN assays. 
The MDBK cell culture conditions, virus propagation conditions, and the virus neutralization assay were 
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Competition ELISA: 96-well Nunc Maxisorp ELISA plates were coated with a bivalent llama-derived 
nanobody in carbonate-bicarbonate buffer directed to E2 protein from BVDV overnight at 4 ºC, followed by a 
blocking step with 1% skim milk the next day for 1 hour at 37 ºC. The subsequent steps were also incubated 
with these conditions. Plates were washed three time with PBS-Tween20 (0.1%) between steps.  Then, 6 
ng/well of BEVS produced APCH-E2 was added to the appropriate wells. Bovine serum samples were added in 
a unique ¼ dilution in PBS-0.05% Tween 20. After a 1 h incubation, a rabbit polyclonal antiserum to E2 was 
added in a dilution 1/40 followed by a peroxidase-labeled anti-rabbit IgG (KPL) at 25 ng/well. The ELISA Ab 
titer was expressed as a percentage of displacement (PD%) of the positive rabbit hyperimmune serum against 
the E2 protein that was considered the 100% signal. The cutoff point of the ELISA was established in PD% = 
10%. Using this assay, the concordance between PD% and vaccine quality was established as follows: low-
quality vaccines <PD 12%, satisfactory vaccines 12% ≤ PD ≤ 35%PD and highly satisfactory vaccines PD> 35% 
(Manuscript under preparation). 
Field trial in cattle: The trial was performed in Estancia Lavalle, Mercedes, Corrientes, Argentina. A 
total of 107 Brangus cows were divided randomly into two groups, 53 vaccinated with the targeted vaccine 
and 54 with a conventional reproductive vaccine, which contains inactivated BVDV. All animals were 
vaccinated twice, beginning on study day 0 and again on study day 30. Blood was drawn from all animals on 
study days 0, 30, 60, 120, 180 300 and 360. Sera were analyzed individually by competition ELISA. Results are 
expressed as a percentage of displacement of a positive hyperimmune serum against the E2 protein. Serum 
samples of all animals at day 0 and 60 (T0 & T60, respectively) were also evaluated by virus neutralization 
assay. The field trial was carried out in a commercial herd under normal management conditions. There were 
no changes in animal feeding, health, movement or any other parameter or condition during the trial.  None 
of the animals had a negative reaction to the targeted vaccine and no mortality was observed in both groups.
Statistical analysis: Differences in mean antibodies values among groups were evaluated by a general 
mixed model of repeated measures throughout time considering vaccine group and time as fixed factors and 
the animal as a random factor followed by Tukey multiple comparisons test. The matrix of variance-
covariance was modeled assuming an AR1 autocorrelation effect due to the sampling of the same animals 
through time (AR1) and heterogenicity of variances at different time points (varIdent). Statistical significance 
was assessed at α ≤0.05 for all comparisons. The analysis was conducted with Infostat software (Infostat® 
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Results
To produce the antigen at industrial scale; the cell culture conditions, the protocol of infection with 
the recombinant baculovirus, and the downstream processing of the antigen, needs to be standardized. In 
order to setup the industrial method, different spinner flasks and bioreactors, customized media with and 
without fetal bovine serum (FBS), culture and infection conditions, and filtration systems were tested and 
analyzed (data not shown). The process was validated using the single-use WAVE™ bioreactor system, SF900 
II serum free media and a two-step filtration system.  As a result, cell concentrations of up to 6 x 106 cells/ml 
were achieved and yielded approximately 5 mg/L of APCH-E2 antigen. This yield allows the production of 3.3 
dose per ml of culture with an antigen production cost that is similar to transgenic plants and lower of 
mammalian cells (Table S1). The flowchart of antigen production is presented in Figure 1. The antigen is then 
formulated with an oil adjuvant (Marcol/Arlacel) to get a water-in-oil stable emulsion. The entire process is 
documented and validated following GMP guidelines.
The Argentinean National Regulatory Authority (SENASA) approved the potency assay described 
above (See Methods).  There was found to be a correlation between the guinea pig VN titer and the bovine 
VN titer:  Log10 titer: 1.37 and Log10 titer 2.03 in guinea pig correlates with Log10 titer 1.54 and Log10 titer 2.13 
in cattle, respectively. These VN titers also correlate with the competition ELISA PD values of 12% and 35% 
respectively (Table S2).
To date, eleven commercial batches of the targeted vaccine has been submitted to SENASA. All of 
them have been approved, with seven being classified as highly satisfactory and four as satisfactory vaccines 
in this guinea pig model. A dot blot graph of NAb titer results for batches 1 to 11 is presented in the Figure 2. 
 A field trial in cattle was performed to evaluate the immune response of this new vaccine and to 
compare the performance of this targeted vaccine with a conventional vaccine formulated with killed BVDV. 
The field trial was carried out in a commercial herd under normal management conditions with approval from 
SENASA. There were no changes in animal feeding, health, movement or any other parameter or condition 
during the trial. On the farm selected to run the trial, there was circulation of BVDV; therefore, neutralizing 
antibody titers against BVDV were observed at the beginning of the study (Figure 3). Taking this into 
consideration, to present the data we subdivided each treatment into two groups: 1) animals with 
competition ELISA PD values ≤35%, and 2) animals with competition ELISA PD values >35% at the start of the 
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the cutoff limit used to evaluate the satisfactory efficacy of vaccines in the SENASA-approved guinea pig 
model (Figure 3 A & B). A significant increase in the NAb titer was observed in the animals within the targeted 
vaccine group that started the trial with a competition ELISA result ≤35%, NAb titers increased from 
Log10(1.43) at T0 to Log10 (2.43) at T60. On the other hand, in the conventional vaccine group at T60 no 
significant change was observed in the NAb titers of the animals regardless of their T0 titers. All the animals in 
both groups were temporally sampled and the immune response was evaluated by ELISA (Figure 4 A, B & C). 
The targeted vaccine group had a greater immunological response than the conventional vaccine based on 
inactivated BVDV virus, in terms of the induction of antibodies to BVDV and the duration of the immune 
response. The targeted vaccine group developed a strong antibody response to BVDV at 30 days after the first 
dose of vaccine (Figure 4A). The antibody titers to BVDV remained high during the trial up to 360 days post-
vaccination. Contrastingly, animals in the conventional vaccine group presented a non-homogeneous 
antibody response; some animals increased their antibody titers while others remained at their basal 
competition-ELISA antibody titers. Significant differences were found between groups at all the timepoints 
analyzed from 30 dpv to the end of the trial. 
To have a better understanding of the performance of the vaccine, animals with a lower level of 
antibody titers (PD ≤35%) at the beginning of the trial were analyzed independently (Figure 4B & 4C). There 
were no significant differences in the mean antibody titers of these animals at day 0 (T0). Results in Figure 4B 
and 4C show that animals that started the trial with PD antibody titers below 35% and were vaccinated with 
the targeted vaccine ultimately reached similar levels of antibody titers to those animals that started with 
PD% titers >35% by the end of the study period. In contrast, the animals in the PD ≤35% antibody titer 
subgroup of the conventional vaccine group had a small increase in antibody titers at day 120, peaking at 27% 
of displacement in the competition ELISA, which then declined by the end of trial (day 360) and finished with 
a mean titer of 9% of displacement in the competition ELISA. Furthermore, these animals within the 
conventional vaccine group never attained similar antibody titers to the conventionally vaccinated animals of 
the PD >35% subgroup.  Within the PD ≤35% subgroup there were eleven seronegative animals (PD≤ 10%), six 
in the targeted vaccine group and five in the conventional vaccine group. The six seronegative animals in the 
targeted vaccine group had a similar antibody increase as those animals in the PD ≤35% subgroup at all the 
timepoints analyzed (T 30, 60, 120, 180, 300 & 360), meaning they responded positively to the vaccine. 
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levels, but the mean titer was lower than the PD ≤35% subgroup at all the timepoints analyzed (data not 
shown).
Discussion
The commercial production and downstream processing of this novel targeted vaccine, was 
established and standardized. The antigen is produced in Sf9 cells using a baculovirus expression vector 
system with customized media in single-use wave bioreactors. It is a flexible technology, with potential 
incorporation of multiple antigens into a single formulation. Studies from our group have previously shown 
that a recombinant subunit vaccine containing BEVS derived E2 proteins from three different strains of BVDV 
(BVDV-1a, -1b and -2a) each, fused to the APCH molecule, was able to induce protection in colostrum-
deprived calves challenged with BVDV (Pecora, Malacari, Perez Aguirreburualde, et al. 2015)..  
The guinea pig model is used by the Argentine government authorities since it is a reliable tool that 
consistently predicts the performance of the vaccine in the field. This model for BVDV vaccine potency testing 
was presented at the XXII Seminar on Harmonization of Registration and Control of Veterinary Medicines 
Americas Committee for Veterinary Medicines (CAMEVET) (https://rr-americas.oie.int/en/events/xxii-
seminar/ Mexico, 2016) and a group of experts from different countries is revising the guideline in order to 
implement this guinea pig model in different American countries (validation study in progress). 
In the cattle field trial, this new targeted vaccine induced a more potent and longer lasting immune 
response when compared to the conventional inactivated vaccine. All animals within the subunit vaccine 
group developed high antibody titer levels at day 30 that remained elevated until the end of the trial at day 
360 post vaccination. In contrast, the conventional vaccine group animals did not have a significant increase 
in antibody titers at days 30 or 60, and subsequently, the antibody levels decreased to basal levels by day 120 
and continued decreasing until the end of the trial. Animals within the subunit targeted vaccine presented 
higher antibody levels after vaccination than the conventional vaccine group at every time-point analyzed. In 
addition, the level of antibodies reached by the targeted vaccine in this field trial are similar to the results 
published by Downey-Slinker et al using a live attenuated vaccine for BVDV (Downey-Slinker et al. 2016) 
suggesting the targeted vaccine may produce similar levels of protection as a live attenuated vaccine, but 
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The northern region of Argentina is characterized as having a wet, hot, and subtropical weather. 
Within cattle herds in this region, such as the one chosen for this field trial, it is common to find animals with 
varying levels of BVDV-specific antibody titers. In these instances, it has previously been shown that animals 
with lower BVDV-specific antibody titers are more susceptible the viral infection (S. R. Bolin and Ridpath 
1996). The main of goal of a BVDV vaccination program is to protect these animals since 90% of PI calves are 
born from non-PI cows (Wittum et al. 2001). In the field trial it was shown (Figure 4C) that the new targeted 
vaccine is able to significantly increase NAbs titers to levels that correlate with protection in these 
seronegative and low-titer animals suggesting an increase in protection from day 30 post-vaccination. This 
potential protection lasted throughout the course of the trial (360 days post-vaccination) (S. R. Bolin and 
Ridpath 1996). On the other hand, the susceptible bovine population within the conventional vaccine group 
had no significant changes in antibody levels after vaccination. 
It is also interesting to note that the standard deviation (SD) of the mean Ab titers in both groups it is 
very different. The SD in the targeted vaccine is, at least, half the SD observed in the conventional vaccine 
group at most of the analyzed timepoints (Figure 4A). This may suggest a more consistent immunological 
response is induced by the targeted vaccine than conventional vaccine or a consequence of circulating BVDV 
in the herd that affected the antibody responses of the two groups differently. It is also clear in Figure 4A that 
at day 0 there is a high degree of variation of antibody levels across the entire heard, ranging from zero to 
87% PD. At day 180, all animals of the targeted vaccine group are concentrated in a range from 55% to 90% 
PD, but animals in the conventional vaccine group exhibit a greater variation, ranging from 16% to 88% PD. In 
the conventional vaccine group, animals with high antibody titers to BVDV at the beginning of the trial 
maintained high antibody titers at the end of the trial. In contrast, animals with no or low antibody titers did 
not increase their antibody level over the course of the trial and, therefore, remained susceptible to virus 
infection. On the other hand, in the targeted vaccine group, all animals reached high antibody titers to BVDV 
independent of their initial antibody titers, indicating the targeted vaccine is able to induce a potent immune 
response in low-titer and, more importantly, in seronegative animals.
The targeted vaccine represents a new and improved vaccine against BVDV with the advantages of 
attenuated vaccines in terms of immunogenicity but with the safety profile of inactivated vaccines. Safety is a 
key issue in BVDV control programs since the vaccination of pregnant cattle with an attenuated vaccine can 
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named, bovine neonatal pancytopenia, has been associated with an inactivated vaccine (Deutskens et al. 
2011). Therefore, veterinarians and farmers demand the introduction of safe and efficacious vaccine. This 
novel subunit targeted vaccine satisfies safety requirements since it can be applied to pregnant cattle without 
the risk of generating PI animals and efficacious requirements since it is potent enough to confer a long-
lasting immune response even in seronegative animals. It implies a reduction in the doses applied over the 
lifespan of a cow, reducing the cost of vaccination and animal movements. It is also a flexible platform that 
can be used to produce a new generation of targeted vaccines against a variety of viral, bacterial, or parasite 
antigens. 
In conclusion, the development of this novel subunit targeted vaccine provides cattle and dairy 
producers with an economical, easily administered, safe, and efficacious BVDV vaccine.
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Figure Captions
Figure 1: Production flowchart of the APCH-E2 antigen.
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Figure 2: Results obtained with all the batches of the targeted vaccine that were approved to be 
released into the market using the guinea pig model of vaccine potency. The dots within each batch (1 to 11) 
represents an individual guinea pig and the lines and bars represent the mean NAb titers  standard 
deviation, the dotted-dashed lines represent the split point for vaccine classification according to SENASA’s 
predetermined level of immunogenicity.
Figure 3: Antibody Response
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Fig 3.B: Competition ELISA
Figure 3 A & B: Antibody responses in all animals of both groups were evaluated by VN assays (Fig 
3.A) at study day 0 and 60 and by a specially designed competitive ELISA to BVDV (Fig 3.B). Light Grey 
Bars: T0 Dark Grey Bars: T60; Striped Bars: Conventional Vaccine; Solid Bars: Targeted Vaccine. For 
bovine samples, a 35% displacement ELISA value correlates with a 1/32 NAb titer. Dotted-dashed lines 
represent the split point for vaccine classification according to SENASA’s predetermined level of 
immunogenicity. *Denotes statistically significant differences (p < 0.05).
Figure 4 A, B & C: Kinetics of antibody response after vaccination
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Fig 4.C: Targeted Vaccine vs Conventional Vaccine. Initial Ab Level < 35%
 
Figure 4 A, B & C: Kinetics of antibody response to BVDV after vaccination. A: All animals; B: animals 
with initial antibody titers >35% by PD-ELISA; C: animals with initial antibody titers <35% PD. 
:Targeted vaccine group; : Conventional vaccine group. Dotted-dashed lines represent the split 
point for vaccine classification according to SENASA’s predetermined level of immunogenicity. 
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